Literature DB >> 21700347

TDP-43 and FUS: a nuclear affair.

Dorothee Dormann1, Christian Haass.   

Abstract

Misfolded TAR DNA binding protein 43 (TDP-43) and Fused-In-Sarcoma (FUS) protein have recently been identified as pathological hallmarks of the neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) characterized by the presence of ubiquitin-positive inclusions (FTLD-U). Although TDP-43 and FUS are normally located predominantly in the nucleus, pathological TDP-43 and FUS inclusions are mostly found in the cytosol. Cytosolic deposition is paralleled by a striking nuclear depletion of either protein. Based on a number of recent findings, we postulate that defects in nuclear import are an important step towards TDP-43 and FUS dysfunction. Failure of nuclear transport can arise from mutations within a nuclear localization signal or from age-related decline of nuclear import mechanisms. We propose that nuclear import defects in combination with additional hits, for example cellular stress and genetic risk factors, may be a central underlying cause of ALS and FTLD-U pathology.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700347     DOI: 10.1016/j.tins.2011.05.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  96 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS).

Authors:  Zi Chao Zhang; Yuh Min Chook
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

3.  TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.

Authors:  Claudia Colombrita; Elisa Onesto; Francesca Megiorni; Antonio Pizzuti; Francisco E Baralle; Emanuele Buratti; Vincenzo Silani; Antonia Ratti
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

4.  The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization.

Authors:  Jasna Lojk; Sonja Prpar Mihevc; Vladimir Boštjan Bregar; Mojca Pavlin; Boris Rogelj
Journal:  Neurotox Res       Date:  2017-04-25       Impact factor: 3.911

5.  Neuron-to-Neuron Transfer of FUS in Drosophila Primary Neuronal Culture Is Enhanced by ALS-Associated Mutations.

Authors:  Sébastien Feuillette; Morgane Delarue; Gaëtan Riou; Anne-Lise Gaffuri; Jane Wu; Zsolt Lenkei; Olivier Boyer; Thierry Frébourg; Dominique Campion; Magalie Lecourtois
Journal:  J Mol Neurosci       Date:  2017-04-20       Impact factor: 3.444

Review 6.  The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.

Authors:  Oliver D King; Aaron D Gitler; James Shorter
Journal:  Brain Res       Date:  2012-01-21       Impact factor: 3.252

Review 7.  Biological Spectrum of Amyotrophic Lateral Sclerosis Prions.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

Review 8.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 9.  Physiological protein aggregation run amuck: stress granules and the genesis of neurodegenerative disease.

Authors:  Benjamin Wolozin
Journal:  Discov Med       Date:  2014-01       Impact factor: 2.970

Review 10.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.